We recently completed a phase 2A multi-center dose-escalation clinical trial for our lead product, LP-10. Results are published in the peer-reviewed journal, International Urology and Nephrology.
Our pipeline asset, LP-310 , was approved by the FDA to begin phase 2A multi-center, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP).
We recently received Orphan Drug Designation from the FDA for our drug candidate, LP-410, which has been designed for the treatment of oral Graft-versus-Host Disease (GVHD). Oral GVHD is a rare but serious oral mucosal disease that currently has no approved therapy. Lipella’s proprietary oral rinse formulation of liposomal tacrolimus has the potential to effectively treat oral GVHD, while minimizing systemic toxicity.
We maintain a pipeline of additional products under development.